Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.68 |
| ▸ | EP300 | Q09472 | 5/20 | 0.68 |
| ▸ | FSCN1 | Q16658 | 4/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TDP2 | O95551 | 1/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.59 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.59 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521861 | 1.00 | KEAP1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL30723351 | 1.00 | KEAP1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510145 | 0.92 | KEAP1 (0.66) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510270 | 0.90 | MCL1 (0.61) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510146 | 0.90 | KEAP1 (0.59) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510149 | 0.90 | HKDC1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510268 | 0.89 | MCL1 (0.64) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510271 | 0.88 | KEAP1 (0.54) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510230 | 0.88 | BRAF (0.70) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL15521814 | 0.88 | KEAP1 (0.70) | KEAP1NFE2L2EP300FSCN1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486319-A1 | COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER | Tvardi Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| EP-4082538-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE MEDICINE (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2023168420-A1 | COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER | TVARDI THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| EP-4082538-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | Baylor College of Medicine (US) | 2022-11-02 | — | — | EP | claimed |
| EP-4069287-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | Baylor College of Medicine (US) | 2022-10-12 | — | — | EP | claimed |
| CN-115023236-A | Therapeutic compounds for methods of use of insulin resistance | 贝勒医学院 | 2022-09-06 | — | — | CN | claimed |
| EP-4633620-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | Tvardi Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4486319-A1 | COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER | Tvardi Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119255793-A | Combination of STAT inhibitor and immune checkpoint inhibitor for the treatment and/or control of cancer | 特维迪疗法公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024129619-A9 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TVARDI THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024129619-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TVARDI THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4376960-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | The Johns Hopkins University (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4082538-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE MEDICINE (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023168420-A1 | COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER | TVARDI THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023010141-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4069287-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | Baylor College of Medicine (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115023236-A | Therapeutic compounds for methods of use of insulin resistance | 贝勒医学院 | 2022-09-06 | — | — | CN | disclosed |